Selected article for: "fusion protein and high affinity"
Author: Hassan, Yasser; Ogg, Sherry; Ge, Hui
Title: Novel Binding Mechanisms of Fusion Broad Range Anti-Infective Protein Ricin A Chain Mutant-Pokeweed Antiviral Protein 1 (RTAM-PAP1) against SARS-CoV-2 Key Proteins in Silico
  • Cord-id: zxo21l4x
  • Document date: 2020_9_17
    • ID: zxo21l4x
    Snippet: The deadly pandemic named COVID-19, caused by a new coronavirus (SARS-CoV-2), emerged in 2019 and is still spreading globally at a dangerous pace. As of today, there are no proven vaccines, therapies, or even strategies to fight off this virus. Here, we describe the in silico docking results of a novel broad range anti-infective fusion protein RTAM-PAP1 against the various key proteins of SARS-CoV-2 using the latest protein-ligand docking software. RTAM-PAP1 was compared against the SARS-CoV-2 B
    Document: The deadly pandemic named COVID-19, caused by a new coronavirus (SARS-CoV-2), emerged in 2019 and is still spreading globally at a dangerous pace. As of today, there are no proven vaccines, therapies, or even strategies to fight off this virus. Here, we describe the in silico docking results of a novel broad range anti-infective fusion protein RTAM-PAP1 against the various key proteins of SARS-CoV-2 using the latest protein-ligand docking software. RTAM-PAP1 was compared against the SARS-CoV-2 B38 antibody, ricin A chain, a pokeweed antiviral protein from leaves, and the lectin griffithsin using the special CoDockPP COVID-19 version. These experiments revealed novel binding mechanisms of RTAM-PAP1 with a high affinity to numerous SARS-CoV-2 key proteins. RTAM-PAP1 was further characterized in a preliminary toxicity study in mice and was found to be a potential therapeutic candidate. These findings might lead to the discovery of novel SARS-CoV-2 targets and therapeutic protein structures with outstanding functions.

    Search related documents:
    Co phrase search for related documents
    • acquire ability and active site: 1
    • acquire ability and acute sars cov respiratory syndrome coronavirus: 1, 2
    • active residue and acute sars cov respiratory syndrome coronavirus: 1, 2
    • active site and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and additional model: 1
    • acute sars cov respiratory syndrome coronavirus and additional model: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and low production cost: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and luciferase assay system: 1
    • acute sars cov respiratory syndrome coronavirus and luciferase expression: 1, 2, 3